Ovarian cancer-associated ascites demonstrates altered immune environment: Implications for antitumor immunity

Anticancer Research

Volumn 29, Issue 8, 2009, Pages 2875-2884

  Giuntoli II, Robert L ^a   Webb, Tonya J ^b   Zoso, Alessia ^b   Rogers, Ophelia ^b   Diaz Montes, Teresa P ^a   Bristow, Robert E ^a   Oelke, Mathias ^b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Ascites; Cell mediated immunity; Chemokines; Cytokines; Ovarian cancer

Indexed keywords

CA 125 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; LYMPHOCYTE SURFACE MARKER; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MELAN A; MELANOMA ANTIGEN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; MUCIN; PLATELET DERIVED GROWTH FACTOR BB; RANTES; TRANSCRIPTION FACTOR FOXP3; TUMOR ANTIGEN; VASCULOTROPIN; VIMENTIN;

ADENOCARCINOMA; ADULT; AGED; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES; CANCER IMMUNOLOGY; CELLULAR IMMUNITY; CLEAR CELL CARCINOMA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENDOMETRIUM CARCINOMA; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNITY; KAPLAN MEIER METHOD; MICROARRAY ANALYSIS; MIXED TUMOR; OVARY CANCER; PERIPHERAL LYMPHOCYTE; PERITONEUM CANCER; PLASMA; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SURVIVAL; T LYMPHOCYTE; TH1 CELL; TH2 CELL; TUMOR ASSOCIATED LEUKOCYTE; UTERINE TUBE CARCINOMA;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; AGED, 80 AND OVER; ANTIGEN-PRESENTING CELLS; ASCITES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHROMIUM; CYSTADENOCARCINOMA, SEROUS; CYTOKINES; ENDOMETRIAL NEOPLASMS; FALLOPIAN TUBE NEOPLASMS; FEMALE; FLOW CYTOMETRY; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROGNOSIS; SURVIVAL RATE; T-LYMPHOCYTES, REGULATORY;

EID: 68549132400     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E et al: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
2. Rosenberg SA, Packard BS, Aebersold PM et al: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 319: 1676-1680, 1988.
3. Dudley ME, Wunderlich JR, Robbins PF et al: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854, 2002.
4. Kobari M, Egawa S, Shibuya K, Sunamura M, Saitoh K and Matsuno S: Effect of intraportal adoptive immunotherapy on liver metastases after resection of pancreatic cancer. Br J Surg 87: 43-48, 2000. (Pubitemid 30042853)
5. Kono K, Takahashi A, Ichihara F et al: Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial. Clin Cancer Res 8: 1767-1771, 2002. (Pubitemid 34633733)
6. Bast RC Jr, Klug TL, Schaetzl E et al: Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigen. Am J Obstet Gynecol 149: 553-559, 1984. (Pubitemid 14086185)
7. Berchuck A: Biomarkers in the ovary. J Cell Biochem Suppl 23: 223-226, 1995.
8. Dong Y, Walsh MD, Cummings MC et al: Expression of MUC1 and MUC2 mucins in epithelial ovarian tumours. J Pathol 183: 311-317, 1997. (Pubitemid 27505217)
9. Frierson HF Jr, Moskaluk CA, Powell SM et al: Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum Pathol 34: 605-609, 2003.
10. Santin AD, Zhan F, Bellone S et al: Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer 112: 14-25, 2004. (Pubitemid 39249487)
11. Ramakrishna V, Ross MM, Petersson M et al: Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T-cells. Int Immunol 15: 751-763, 2003. (Pubitemid 36675806)
12. Santin AD, Hermonat PL, Ravaggi A et al: In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer. Am J Obstet Gynecol 183: 601-609, 2000.
13. Zhang L, Conejo-Garcia JR, Katsaros D et al: Intratumoral T-cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348: 203-213, 2003. (Pubitemid 36077915)
14. Aoki Y, Takakuwa K, Kodama S et al: Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer. Cancer Res 51: 1934-1939, 1991.
15. Fujita K, Ikarashi H, Takakuwa K et al: Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes. Clin Cancer Res 1: 501-507, 1995.
16. Valmori D, Fonteneau JF, Valitutti S et al: Optimal activation of tumor-reactive T-cells by selected antigenic peptide analogues. Int Immunol 11: 1971-1980, 1999.
17. Brossart P, Heinrich KS, Stuhler G et al: Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 93: 4309-4317, 1999.
18. Rongcun Y, Salazar-Onfray F, Charo J et al: Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J Immunol 163: 1037-1044, 1999. (Pubitemid 29328117)
19. Thomas AM, Santarsiero LM, Lutz ER et al: Mesothelin-specific CD8(+) T-cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med 200: 297-306, 2004.
20. Trojan A, Witzens M, Schultze JL et al: Generation of cytotoxic T lymphocytes against native and altered peptides of human leukocyte antigen-A*0201 restricted epitopes from the human epithelial cell adhesion molecule. Cancer Res 61: 4761-4765, 2001. (Pubitemid 32691888)
21. Oelke M, Kurokawa T, Hentrich I et al: Functional characterization of CD8(+) antigen-specific cytotoxic T lymphocytes after enrichment based on cytokine secretion: comparison with the MHC-tetramer technology. Scand J Immunol 52: 544-549, 2000. (Pubitemid 32011766)
22. Hildesheim A, Ryan RL, Rinehart E et al: Simultaneous measurement of several cytokines using small volumes of biospecimens. Cancer Epidemiol Biomarkers Prev 11: 1477-1484, 2002. (Pubitemid 35340388)
23. Oelke M, Maus MV, Didiano D, June CH, Mackensen A and Schneck JP: Ex vivo induction and expansion of antigen-specific cytotoxic T-cells by HLA-Ig-coated artificial antigen-presenting cells. Nat Med 9: 619-624, 2003. (Pubitemid 36597110)
24. Dunbar PR, Ogg GS, Chen J, Rust N, van der Bruggen P and Cerundolo V: Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood. Curr Biol 8: 413-416, 1998. (Pubitemid 28174001)
25. Rubio V, Stuge TB, Singh N et al: Ex vivo identification, isolation and analysis of tumor-cytolytic T-cells. Nat Med 9: 1377-1382, 2003. (Pubitemid 37466186)
26. + melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy. Clin Cancer Res 6: 1997-2005, 2000.
27. + T-cell response to dendritic cells genetically engineered to express the MART-1/Melan-A gene. Cancer Res 58: 5305-5309, 1998.
28. Kalbfleisch JD and Prentice RL: The Statistical Analysis of Failure Time Data. New York: Wiley, 1980.
29. Oelke M, Krueger C, Giuntoli RL, 2nd and Schneck JP: Artificial antigen-presenting cells: artificial solutions for real diseases. Trends Mol Med 11: 412-420, 2005. (Pubitemid 41254044)
30. Ioannides CG, Platsoucas CD, Rashed S, Wharton JT, Edwards CL and Freedman RS: Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites. Cancer Res 51: 4257-4265, 1991.
31. Santin AD, Hermonat PL, Ravaggi A et al: Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer. Gynecol Obstet Invest 51: 254-261, 2001. (Pubitemid 32620125)
32. +/regulatory T-cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 102: 18538-18543, 2005. (Pubitemid 43011261)
33. Curiel TJ, Coukos G, Zou L et al: Specific recruitment of regulatory T-cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942-949, 2004. (Pubitemid 39273735)
34. Mesiano S, Ferrara N and Jaffe RB: Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 153: 1249-1256, 1998. (Pubitemid 28465848)
35. Chen CK, Wu MY, Chao KH, Ho HN, Sheu BC and Huang SC: T lymphocytes and cytokine production in ascitic fluid of ovarian malignancies. J Formos Med Assoc 98: 24-30, 1999.
36. Mustea A, Konsgen D, Braicu EI et al: Expression of IL-10 in patients with ovarian carcinoma. Anticancer Res 26: 1715-1718, 2006.
37. Xie X, Ye D, Chen H, Lu W, Cheng B and Zhong H: Interleukin-7 and suppression of local peritoneal immunity in ovarian carcinoma. Int J Gynaecol Obstet 85: 151-158, 2004. (Pubitemid 38510229)
38. Rabinowich H, Suminami Y, Reichert TE et al: Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma. Int J Cancer 68: 276-284, 1996. (Pubitemid 26384127)
39. Merritt WM, Lin YG, Spannuth WA et al: Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst 100: 359-372, 2008.
40. Hirahara N, Nio Y, Sasaki S et al: Inoculation of human interleukin-17 gene-transfected Meth-A fibrosarcoma cells induces T-cell-dependent tumor-specific immunity in mice. Oncology 61: 79-89, 2001. (Pubitemid 32727592)
41. Matei D, Kelich S, Cao L et al: PDGF-BB induces VEGF secretion in ovarian cancer. Cancer Biol Ther 6: 1951-1959, 2007.
42. Shen GH, Ghazizadeh M, Kawanami O et al: Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer 83: 196-203, 2000. (Pubitemid 30411717)
43. Burger RA, Sill MW, Monk BJ, Greer BE and Sorosky JI: Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25: 5165-5171, 2007. (Pubitemid 350237599)
44. Loberg RD, Ying C, Craig M et al: Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res 67: 9417-9424, 2007. (Pubitemid 47535932)
45. Tsukishiro S, Suzumori N, Nishikawa H, Arakawa A and Suzumori K: Elevated serum RANTES levels in patients with ovarian cancer correlate with the extent of the disorder. Gynecol Oncol 102: 542-545, 2006. (Pubitemid 44353649)
46. Lu J, Giuntoli RL 2nd, Omiya R, Kobayashi H, Kennedy R and Celis E: Interleukin 15 promotes antigen-independent in vitro expansion and long-term survival of antitumor cytotoxic T lymphocytes. Clin Cancer Res 8: 3877-3884, 2002.
47. Kim DK, Kim JH, Kim YT, Kim JW and Ioannides CG: The comparison of cytotoxic T-lymphocyte effects of dendritic cells stimulated by the folate binding protein peptide cultured with IL-15 and IL-2 in solid tumor. Yonsei Med J 43: 691-700, 2002.
48. Nishimura F, Dusak JE, Eguchi J et al: Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10. Cancer Res 66: 4478-4487, 2006.
49. Luo X, Yu Y, Liang A et al: Intratumoral expression of MIP-1beta induces antitumor responses in a pre-established tumor model through chemoattracting T-cells and NK cells. Cell Mol Immunol 1: 199-204, 2004.
50. Curiel TJ, Cheng P, Mottram P et al: Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res 64: 5535-5538, 2004. (Pubitemid 39095544)